Introduction {#s0001}
============

Diabetes mellitus type 1 (insulin-dependent diabetes mellitus) is classified under metabolic disorder caused by the autoimmune destruction of pancreatic β-cells. Insulin is secreted by pancreatic β-cells which help to reduce the blood glucose level. Patients with type 1 diabetes require taking the exogenous insulin by injections on an interval of time in a day. About 5--10% (5--50 million) of all the diabetes patients are type 1 diabetes which is a huge number world-wide. Generally, type 1 diabetes is found in adolescence or childhood, but it can appear at any stage of age. People, who are at risk of developing type 1, can be identified by genetic markers and auto-antibodies which target the β-cells, insulin, glutamic acid decarboxylase (GAD), tyrosine phosphate IA-2, IA-2β, and ZnT8. These auto-antibodies are found in either one or more than one individual, who suffer from type 1 diabetes.[@cit0011] An individual suffering from type 1 diabetes may suffer from weight loss, polyuria, blurred vision, polyphagia, and polydipsia. It may also cause stupor, coma in uncontrolled condition and if not treated then it may lead to death because of ketoacidosis or by non-ketotic hyperosmolar syndrome.[@cit0013]

During the diabetes condition, the most affected organs are liver and kidney. The liver plays a very important role in the maintenance of glucose levels in the body. It regulates the metabolism of glucose by using glucose molecules as an energy source. It also has a tendency to synthesize glycogen from non-carbohydrate compounds. Diabetes mellitus may lead to liver associated disease as Non-alcoholic fatty liver disease (NAFLD). The abnormal level of liver enzymes, ie, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) may be symptoms of NAFLD. ALT has been considered as the marker for NAFLD and AST along with ALP are the indicators of hepatocellular injury.[@cit0014],[@cit0018] ALP is released in the blood and plasma due to the damage of the liver and its normal range falls between 44--147 IU/L.[@cit0009]

A kidney is the most common organ to get affected and the disease caused by diabetes is called Diabetic Nephropathy (DN). DN is a clinical condition in diabetes where renal function and structure of the kidney gets disrupted. To monitor the kidney function test, the easiest way is to analyze the Blood Urea Nitrogen (BUN) and creatinine level in blood. These are the waste products produced due to the metabolic breakdown of protein and creatine and excreted by the kidney. During kidney disease, these materials including others, accumulate in the body which result in the elevation of urea and creatinine level. In normal condition the BUN level should range between 7--20 mg/dL and creatinine level should be 0.8--1.4 mg/dL.[@cit0004] Uric acid is a waste material which is filtered by the kidney. If a kidney is not working properly then uric acid accumulates in the body and causes gout disease.

Inspite of many drugs and strategies for type 1 diabetes mellitus, they have some side effects and limitations, so these drugs require perpetual improvement. Natural medicines are being used since ancient times for the treatment of diabetes mellitus.[@cit0027] The natural compounds may help to restore and maintain the numbers of pancreatic β-cells. These natural compounds can be found in some plants and in some edible mushrooms which are macrofungi. People in Asian countries like India and China were well versed with the culinary effects of these mushrooms. Mushrooms have many species, some of them are poisonous and some are edible. Oyster mushroom (*Pleurotus*) is one of the edible mushrooms, contains vitamins (A, B, C, D, K) and dietary fibers like α/β-glucans and chitin.[@cit0019] They are very good in Reactive Oxygen Species (ROS) scavenging activity, which is also a cause of diabetes mellitus.

*Pleurotus* mushroom has many species that have been tested for their medicinal and nutritional value. Among them, *Pleurotus ostreatus* has been tested for anti-cancerous and anti-diabetic properties in the in vitro cell lines and on the animal model.[@cit0024],[@cit0026] *Pleurotus abalones, Pleurotus sajor-caju, Pleurotus citrinopileatus, Pleurotus pulmonarius, Pleurotus eryngii*[@cit0005] have been used to explore their anti-diabetic properties, all of these have shown to lower the blood glucose level but not very efficiently, so the searching of other species with greater potential to lower the blood glucose level was required.

The present study determined the properties of *P. fossulatus* aqueous extract to reduce not only the blood glucose level but also provides the protection to liver and kidney from harmful effects during diabetic conditions.

Materials and Methods {#s0002}
=====================

Chemicals Required {#s0002-s2001}
------------------

Streptozotocin (STZ) was used to induce diabetes and metformin was used as a drug control. All the chemicals and solvent used were analytical grade and purchased from Himedia and Merck. The biochemical assays were performed by the Star 21 Plus Semiautomatic Biochemistry Analyzer.

Mushroom Extract Preparation {#s0002-s2002}
----------------------------

*Pleurotus fossulatus* was cultivated in Mushroom Biotechnology lab, Centre of Biotechnology, University of Allahabad, India. The fruiting body was air-dried under shade for five days, then prepared the powder by using a grinder.

The magnetic-stirrer-based extraction of *P. fossulatus* was performed. For the extraction, we took 100 gm powder of *P. fossulatus* and mixed with 1000 mL milli q water and kept at 60°C temperature for 72 hours. During this time continuous stirring by magnetic bead was allowed. The extract was filtered twice by Whatman no.1 filter paper and dried by using water-bath at 60°C. The total percentage yield of extract was 25% w/w.

Animal Experiments Design {#s0002-s2003}
-------------------------

Albino Wistar rats weighing 175 ± 25 gm were used for all experiments in the present study. The sex of animals used in the study was male, collected at random from the animal house of the University of Allahabad. Animals were housed in separate cages under controlled conditions of temperature (22 ± 2°C). All animals were given a standard diet (Golden feed, New Delhi, India) and water ad libitum. Animals were kept at 12:12 hours, light: dark cycle. Animals were further divided into five groups with six animals in each group.

Group I received normal saline P.O. (by opening/orally) only and served as vehicle control, Group II, III, IV, and V were diabetic, induced by streptozotocin (STZ). Group II received saline only for 21 days. Group III received metformin, 100 mg/kg/day P.O., group IV received extract 250 mg/kg/day P.O., and group V received extract 500 mg/kg/day P.O. All dosing of the test sample was done P.O. throughout the experiment.

Induction of Diabetes {#s0002-s2004}
---------------------

Diabetes was induced in rats by intraperitoneal injection (i.p.) of STZ at a dose of 60 mg/kg body weight. STZ was dissolved in ice-cold 0.1M citrate buffer. The animals were allowed to drink 5% glucose solution overnight to overcome STZ-induced hypoglycemia. The animals were considered diabetic if their blood glucose value was above 200 mg/dl on 3rd day of STZ injection. The treatment was continued till 21 days; blood glucose level and body weights were measured on 0, 4, 8, 12, 16, and 21 days of post-treatment.

Separation of Plasma from the Blood {#s0002-s2005}
-----------------------------------

For the separation of plasma, 5 mL of blood was collected in an anticoagulant (EDTA) containing a centrifuge tube. The tube was centrifuged at 3000 rpm for 20 minutes. RBCs and plasma were separated in pallets and supernatant, respectively. The plasma was collected in a separate vial.

Effects of PFA-Extract on Plasma Lipid Profiling {#s0002-s2006}
------------------------------------------------

Plasma was used to test the total cholesterol (TC), and high-density lipoprotein (HDL) (catalog number- CHOD-PAP, 71LS200-75) and triglyceride (TG) (catalog number- GPO-PAP, 72LS100-40) were estimated by using kits purchased from Arkray Healthcare Pvt. Ltd, Mumbai, India. All the samples and standards were prepared according to the instructions, given in the catalogue.

Effects of PFA-Extract on Liver Function {#s0002-s2007}
----------------------------------------

Plasma was used to determine the alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) by using kits with catalog no. 75DP200-20, 76LS200-60, 77LS200-60, respectively, purchased from Arkray Healthcare Pvt. Ltd, Mumbai, India. All the samples and standards were prepared according to the instructions, given in the catalogue.

Effects of PFA-Extract on Kidney Function {#s0002-s2008}
-----------------------------------------

Creatinine (CRT), blood urea nitrogen (BUN), and uric acid were estimated in plasma by kit-based method, purchased from Erba Mannheim Pvt. Ltd with catalog no. 120,246, 120,214, and 120,185, respectively. All the samples and standards were prepared according to the instructions, given in the catalogue.

Histology of Liver {#s0002-s2009}
------------------

The liver from each group was removed, washed with saline and kept in 10% formalin solution. After washing the liver was transferred in mixture of absolute alcohol and xylene (1:1) for 15--20 minutes. The tissues were put in xylene for 30 minutes. The paraffin blocks were prepared and the sections of 5 μm thickness were cut by a microtome. The sections were transferred to slides and de-waxed with xylene. The sections were stained with hematoxylin solution for 30 minutes and subsequently counterstained with eosin and then mounted.

Statistical Analysis {#s0002-s2010}
--------------------

The data of body-weight and blood glucose level were analyzed by two-way ANOVA and rest other data were analyzed by one-way ANOVA followed by the Bonferroni test. P\<0.05 was considered as a level of significance. All data are presented in Mean ± SD. The graphs were plotted by using GraphPad Prism5 software.

Results {#s0003}
=======

The Effect of PFA-Extract on Body Weight {#s0003-s2001}
----------------------------------------

The effect of *P. fossulatus* aqueous extract (PFA-extract) on the body weight of rats is given in [Table 1](#t0001){ref-type="table"} and statistical comparison is shown in [Figure 1](#f0001){ref-type="fig"}. There was a significant difference (P\<0.05) in the body weight of diabetic control, D1, and D2 groups as compared to normal control before the commencement of the experiment. But after 4 days of the experiment, there was no significant difference in the body weight of these groups. The diabetic control and drug control groups showed a significant difference (P\<0.05) at 12th and 16th days but the test groups, ie, D1 and D2 had no significant difference. However, the D2 group showed significant (P\<0.05) improvement in body weight after 21 days of dosing and recovered by 97.9% whereas, drug control recovered 98.6%.Table 1The Effects of PFA-Extract on Body Weight in RatsTreatment\
GroupsBody Weight (g)0 Days4 Days8 Days12 Days16 Days21 DaysNormal (Saline 5 mL/kg)164.66±3.881165.41±3.647165.5±3.512165.51±3.887167.21±5.882167.3±5.789Diabetic (Saline 5 mL/kg)185.83±5.492170.28±1.958164.95±2.260155.63±2.791149.6±1.577143.92±0.766Drug (Metformin 100 mg/kg)165±4.147149.35±5.124150.45±4.954152.73±4.495156.31±4.473162.83±4.542D1 (250 mg/kg)178.5±3.937161.33±5.689162.16±5.558162.58±5.427164.66±4.980168.9±4.626D2 (500 mg/kg)180.33±3.777160.95±5.499164.66±5.443167.38±5.175172.5±4.150176.65±3.983[^1] Figure 1The comparison of PFA-extract effects on body weight in rats. All the data were presented as mean ± SD. Groups are; normal control, diabetic control, drug control (metformin 100 mg/kg), D1 (dosing group 1; 250 mg/kg), and D2 (dosing group 2; 500 mg/kg). ^a^P\<0.05 for comparison with the normal control group. ^b^P\<0.05 for comparison with the diabetic control group.

The Effect of PFA-Extract on Blood Glucose Level (BGL) {#s0003-s2002}
------------------------------------------------------

The effect of PFA-extract on rats is shown in [Table 2](#t0002){ref-type="table"} and statistical comparison is given in [Figure 2](#f0002){ref-type="fig"}. The blood glucose level of diabetic control was slightly higher than the normal group before the commencement of the experiment. There was a sharp increase of BGL in all groups observed except normal control on 4th day. On the 8th and 12th day of the drug control experiment, D1, and D2 groups started to reduce significantly (P\<0.05) as compared to normal and diabetic control groups. After 21 days of the treatment, the BGL reduced by 35.7%, 53.0%, and 55.3% of D1, D2, and drug control groups, respectively, and the D2 group showed no significant difference (P\<0.05) as compared to the normal group.Table 2The Effect of PFA-Extract on BGL in RatsTreatment\
GroupsBlood Glucose Level (mg/dl)0 Days4 Days8 Days12 Days16 Days21 DaysNormal (Saline 5 mL/kg)84.33±3.38686.83±1.94088.83±1.94090.16±1.94091.16±2.31692.16±2.316Diabetic (Saline 5 mg/kg)97.00±2.366215.50±6.156304.66±4.966328.83±10.925356.5±9.354385.00±6.131Drug (Metformin 100 mg/kg)85.16±3.060211.33±7.174198.00±3.224168.50±14.293111.16±6.55494.33±2.581D1 (250 mg/kg)86.16±2.786223.16±12.155210.83±6.675181.00±6.196160.33±7.890143.50±5.244D2 (500 mg/kg)86.83±3.188220.16±6.337190.00±3.577164.83±4.215117.5±4.505103.33±4.885[^2] Figure 2The comparison of PFA-extract effects on blood glucose levels in rats. All the data were presented as mean ± SD. Groups are; normal control, diabetic control, drug control (metformin 100 mg/kg), D1 (dosing group 1; 250 mg/kg), and D2 (dosing group 2; 500 mg/kg). ^a^P\<0.05 for comparison with the normal control group. ^b^P\<0.05 for comparison with the diabetic control group.

The Effect of PFA-Extract on Lipid Profiling {#s0003-s2003}
--------------------------------------------

The effect of PFA-extract on lipid profile is depicted in [Table 3](#t0003){ref-type="table"} and the statistical comparison is shown in [Figure 3](#f0003){ref-type="fig"}. In this study, we analyzed total cholesterol (TC), triglyceride (TG), and high-density lipoprotein. The D2 group showed a significant reduction (P\<0.0001) of TC and TG levels when compared to the diabetic control group and there was a slight difference (P\<0.05) as compared to the normal control group. The HDL level was highest (P\<0.0001) in the D2 group than normal and drug control groups.Table 3The Effect of PFA-Extract on Lipid Profile in RatsTreatment GroupsTCTGHDLNormal control83.90±1.37569.63±1.37424.96±0.896Diabetic control147.98±5.134125.06±4.99410.39±0.645Drug control89.78±2.38173.91±1.81325.86±2.381Test D1 (250 mg/kg)139.69±5.031118.94±5.03114.79±1.960Test D2 (500 mg/kg)92.31±3.78880.85±8.96231.35±1.781[^3][^4] Figure 3The comparison of PFA-extract effects on HDL (high density lipoprotein), TC (total cholesterol), and TG (triglyceride) in rats. All the data were presented as mean ± SD. Groups are; normal control, diabetic control, drug control (metformin 100 mg/kg), D1 (dosing group 1; 250 mg/kg), and D2 (dosing group 2; 500 mg/kg). \*\*\*Denotes P\< 0.0001, \*\*P\< 0.001, \*P\< 0.05, and ns denotes 'no level of significance' versus normal control, diabetic control and drug control.

The Effect of PFA-Extract on Liver Function {#s0003-s2004}
-------------------------------------------

The effect of PFA-extract on liver function is given in [Table 4](#t0004){ref-type="table"} and the statistical comparison is depicted in [Figure 4](#f0004){ref-type="fig"}. Three enzymes were examined, ie, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatases (ALP). The AST level was significantly (P\<0.0001) reduced to normal level in the D2 group whereas, the D1 group had a low significant difference (P\<0.001) as compared with the diabetic control group and there was no significant difference with the normal control group. The ALT and ALP levels reduced significantly (P\<0.05), (P\<0.0001) in the D2 group as compared with the normal control group.Table 4The Effect of PFA-Extract on Liver Function in RatsTreatment GroupsASTALTALPNormal control139.08±7.30349.50±5.916114.80±6.557Diabetic control159.41±9.58075.43±3.819213.57±6.151Drug control120.51±4.39047.73±5.323122.81±3.295Test D1 (250 mg/kg)145.17±4.59469.24±4.095172.82±3.211Test D2 (500 mg/kg)132.01±5.55358.63±4.390143.26±2.423[^5][^6] Figure 4The comparison of PFA-extract effects on ALP (alkaline phosphatase), ALT (alanine aminotransferase), and AST (aspartate aminotransferase) in rats. All the data were presented as mean ± SD. Groups are; normal control, diabetic control, drug control (metformin 100 mg/kg), D1 (dosing group 1; 250 mg/kg), and D2 (dosing group 2; 500 mg/kg). \*\*\*Denotes P\< 0.0001, \*\*P\< 0.001, \*P\< 0.05, and ns denotes 'no level of significance' versus normal control, diabetic control and drug control.

The Effect of PFA-Extract on Kidney Function {#s0003-s2005}
--------------------------------------------

The effect of PFA-extract on creatinine (CRT), blood urea nitrogen (BUN), and uric acid is mentioned in [Table 5](#t0005){ref-type="table"} and statistical comparison is shown in [Figure 5](#f0005){ref-type="fig"}. After 21 days of dosing, the CRT level in D1 and D2 group was found normal and had no significant difference with the normal control group. There was a significant difference (P\<0.0001) (P\<0.0001) of BUN and uric acid level was observed, respectively, in D1, and D2 groups when compared with the normal control group.Table 5The Effect of PFA-Extract on Kidney Function in RatsTreatment GroupsCreatinineBUNUric AcidNormal control0.628±0.027817.71±0.6434.24±0.236Diabetic control1.93±0.49730.79±0.8369.21±0.326Drug control0.685±0.01813.99±0.5705.18±0.285Test D1 (250 mg/kg)0.784±0.02121.78±0.5307.27±0.247Test D2 (500 mg/kg)0.656±0.070715.13±1.4636.27±0.325[^7][^8] Figure 5The comparison of PFA-extract effects on BUN (blood urea nitrogen), CRT (creatinine), and uric acid in rats. All the data were presented as mean ± SD. Groups are; normal control, diabetic control, drug control (metformin 100 mg/kg), D1 (dosing group 1; 250 mg/kg), and D2 (dosing group 2; 500 mg/kg). \*\*\*Denotes P\< 0.0001, P\< 0.05, and ns denotes 'no level of significance' versus normal control, diabetic control and drug control.

Observations of Liver Histology {#s0003-s2006}
-------------------------------

As shown in [Figure 6](#f0006){ref-type="fig"}, all the images of liver histo-slides were taken at 400X from Olympus microscope (modal; CKX53, camera model; Megcam-MU2A). Normal control group had normal structure of hepatocytes with regular radial morphology of hepatic architecture with normal sinusoids. Diabetic group had many pathological changes, characterized as increased number of kuffer cells, monocytes, dilatation of sinusoids, and narcosis. Whereas, drug control group had improved dilatation of sinusoids, normal kuffer cells, and improved hepatic architecture compared with normal control. D1 and D2 group showed significant improvement, characterized as improved hepatic architecture, reduced kuffer cells, and improved sinusoids, as compared with normal control and drug control groups.Figure 6Histopathology of rat liver. Different groups of rat liver (400X) stained with hematoxylin and eosin.**Abbreviations:** Panel A, normal control; B, diabetic control; C, drug control; D, D1 group; E, D2 group; Hc, hepatocytes; Pv, portal vain; S, sinusoid; Mc, monocytes; Kc, kuffer cells; Cv, central vain.

Discussion {#s0004}
==========

DM is a complex and serious metabolic disorder which can affect the major vital functions of the body. There are about 390 million people suffering from DM, world-wide. These numbers are expected to rise by 500 million by 2030.[@cit0015] There is no permanent treatment for the DM till now, but few oral/injection-based therapies are used to control the blood glucose level (BGL) and protect from adverse effects. The therapies are; insulin, metformin, biguanides, α-amylase, and α-glucosidase inhibitors, sulfonylureas.[@cit0025] Due to the possibility of adverse/side effects of these synthetic medicines, these are less preferred than natural hypoglycemic agents, which can have less side-effect. Edible mushrooms are used as hypoglycemic agents from ancient time.[@cit0005] *P. fossulatus* is a species of oyster mushroom, cultivated in Microbial and Mushroom Biotechnology Lab of Centre of Biotechnology, University of Allahabad, India. For the first time, we are reporting its antidiabetic property along with protective effect on the liver, kidney, and pancreas. This study was carried to determine the effects of PFA-extract on BGL, body weight, lipid profile, kidney function and liver function on the STZ-induced diabetic rat model.

Streptozotocin (STZ) is a diabetogenic agent, causes irreversible damage to the pancreatic β-cells, resulting in impaired secretion of insulin.[@cit0022] STZ-induced diabetes rat generally considered as diabetes type 1 models because animals start to lose body weight drastically, which have already been reported by the researchers.[@cit0007],[@cit0010] The loss of body weight is caused by the degradation of structural protein, which participates in the building of body weight.[@cit0012] Previous reports suggest that protein synthesis decreased because of a low level of ATP formation in insulin-deficient animals.[@cit0021] The present study suggests that the PFA-extract at 500 gm dose improves the body weight by 97.9% in the STZ-induced diabetic rat model ([Table 1](#t0001){ref-type="table"}; [Figure 1](#f0001){ref-type="fig"}). The possible mechanism behind this, as it improves the secretion of insulin and promotes ATP formation which further promotes the synthesis of structural proteins. So, *P. fossulatus* can be very helpful in controlling diabetes if it is given with other definite medicines.

The elevated level of blood glucose is always a serious concern because it could hamper the vital functions of many organs like kidney function, liver function and cause eye-related problems. So, it is necessary to reduce the blood glucose level and improve the complications associated with diabetes.[@cit0002],[@cit0003],[@cit0024] In the present study, the PFA-extract reduced the blood glucose level significantly in STZ-induced diabetic rats. The D2 group which received 500 mg/kg of body weight dose was found the most effective than the D1 group which received the lowest dose, ie, 250 mg/kg of body weight. The possible mechanism behind the PFA-extract's hypoglycemic activity is because of its insulin-releaser action and recovery of β-cells.[@cit0016] Ng et al (2015)[@cit0019] also reported hypoglycemic and antidiabetic activity of *P. sajor-caju* aqueous extract on STZ-induced diabetic rats which further confirms the relevance of our work. Due to its efficacy in controlling the blood glucose levels, *P. fossulatus* could be a potential natural antidiabetic agent.

Destruction of β-cells causes the reduction of insulin secretion which leads to low lipoprotein lipase activity and elevated level of free fatty acids from fat tissues, this results in hyperlipidemia condition, which is associated with uncontrolled diabetes type 1. From studies, it has been reported that TC, TG level in blood increases whereas, HDL level decreases.[@cit0001],[@cit0006],[@cit0017] Our results showed the same pattern, ie, TC and TG level elevated and HDL level decreased. After treatment with the PFA-extract, at 500 mg dosing, TC and TG levels were found significantly low whereas, HDL level increased maximum ([Figure 3](#f0003){ref-type="fig"}). The results showed that a 500 mg dose can reduce the risk of cardiovascular disease and help in the removal of cholesterol. The improved hyperlipidemia condition may be due to the improvement of insulin secretion because insulin controls the biosynthesis of cholesterol and reduces the level of lipolysis.[@cit0008]

The high blood glucose level in diabetic patients can impair liver function. The elevated level of serum AST, ALT, and ALP in a diabetic patient can be a screening marker of liver damage.[@cit0023] Whenever the organs get injured, their tissues release AST, ALT, and ALP into the bloodstream whereas the increased number of kuffer cells and monocytes can be seen in tissues of liver ([Figure 6](#f0006){ref-type="fig"}), this is why the histopathology and these enzymes have been estimated.[@cit0009] The effect of PFA-extract on AST, ALT, and ALP was also checked and we found that our 500 mg concentration of dose showed to lower these enzymes effectively ([Figure 4](#f0004){ref-type="fig"}), as compared with normal and diabetic control groups.

High blood glucose levels could damage the kidney and hamper its filtration rate. In diabetic conditions, the kidney grows large, and glomerular filtration rate (GFR) gets impaired.[@cit0004] BUN is a clinical diagnostic marker for acute and chronic kidney disease. The excess level of creatinine in blood is an indicator of impaired GFR which is a sign of renal injury. In another study, the researcher found that the estimated glomerular filtration rate (eGFR) is independently associated with serum uric acid, which is an indicator of the damaged kidney.[@cit0020] In our study, we found that the 500 mg concentration of PFA-extract can reduce the creatinine and BUN level effectively (no significant difference was found as compared with the drug control group) whereas uric acid level reduced significantly as compared with normal and diabetic control (but less effective than the drug control group) ([Figure 5](#f0005){ref-type="fig"}).

Conclusion {#s0005}
==========

The PFA-extract showed its potential to lower the adverse effects on vital organs, ie, liver, kidney, and pancreas in the diabetes type 1 rat model. The aqueous extract had the potential to control body weight and reduce the blood glucose level. It also had shown the tendency to modulate the lipid profile which can be very helpful in prevention or mitigation of cardiovascular disease. The possible mechanism behind its protective effects may be due to the regeneration property of pancreatic β-cells which improved insulin secretion. The main bioactive molecules of *P. fossulatus* are still unknown; it requires further investigations. To the best of our knowledge, no one has reported such kind of attributes of *P. fossulatus* before.
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[^1]: **Notes:** The data were presented as mean ± SD, n = 6, Groups; Normal control, Diabetic control, Drug control, D1 (dosing group 1), D2 (dosing group 2).

[^2]: **Notes:** The data were presented as mean ± SD, n = 6, Groups; Normal control, Diabetic control, Drug control, D1 (dosing group 1), D2 (dosing group 2).

[^3]: **Notes:** The data were presented as mean ± SD, n = 6, Groups; Normal control, Diabetic control, Drug control, D1 (dosing group 1), D2 (dosing group 2).

[^4]: **Abbreviations:** HDL, high-density lipoprotein; TC, total cholesterol; TG; triglyceride.
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